1. Home
  2. FOLD vs RNST Comparison

FOLD vs RNST Comparison

Compare FOLD & RNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • RNST
  • Stock Information
  • Founded
  • FOLD 2002
  • RNST 1904
  • Country
  • FOLD United States
  • RNST United States
  • Employees
  • FOLD N/A
  • RNST N/A
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • RNST Major Banks
  • Sector
  • FOLD Health Care
  • RNST Finance
  • Exchange
  • FOLD Nasdaq
  • RNST Nasdaq
  • Market Cap
  • FOLD 2.9B
  • RNST 3.3B
  • IPO Year
  • FOLD 2007
  • RNST N/A
  • Fundamental
  • Price
  • FOLD $6.12
  • RNST $38.52
  • Analyst Decision
  • FOLD Buy
  • RNST Buy
  • Analyst Count
  • FOLD 10
  • RNST 6
  • Target Price
  • FOLD $16.22
  • RNST $42.20
  • AVG Volume (30 Days)
  • FOLD 5.5M
  • RNST 548.7K
  • Earning Date
  • FOLD 08-07-2025
  • RNST 07-22-2025
  • Dividend Yield
  • FOLD N/A
  • RNST 2.27%
  • EPS Growth
  • FOLD N/A
  • RNST 31.26
  • EPS
  • FOLD N/A
  • RNST 3.20
  • Revenue
  • FOLD $543,141,000.00
  • RNST $710,265,000.00
  • Revenue This Year
  • FOLD $19.87
  • RNST $40.84
  • Revenue Next Year
  • FOLD $23.15
  • RNST $13.45
  • P/E Ratio
  • FOLD N/A
  • RNST $12.02
  • Revenue Growth
  • FOLD 28.25
  • RNST 15.97
  • 52 Week Low
  • FOLD $5.51
  • RNST $26.97
  • 52 Week High
  • FOLD $12.65
  • RNST $39.63
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 51.42
  • RNST 66.56
  • Support Level
  • FOLD $5.66
  • RNST $37.38
  • Resistance Level
  • FOLD $6.45
  • RNST $38.91
  • Average True Range (ATR)
  • FOLD 0.21
  • RNST 0.79
  • MACD
  • FOLD 0.07
  • RNST 0.21
  • Stochastic Oscillator
  • FOLD 64.89
  • RNST 91.18

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

About RNST Renasant Corporation

Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.

Share on Social Networks: